Biotech Series B Investors & VC Firms
724 firms in this list, with a median first check of $500K. 165 of them lead rounds. Generated from verified public data and updated continuously.
AN Venture Partners
TokyoSeed–Growth
22 people
New Alliance Capital
ShanghaiSeed–Late Stage
25 people
Clay Capital
Seed–Series C$3M – $8M
18 people
Invus
New YorkSeed–Late Stage
8 people
Limburgse Reconversie Maatschappij
HasseltSeed–Growth$27K – $10.8M
22 people
MSD Global Health Innovation Fund
RahwaySeries A–Late Stage$2M – $10M
10 people
Alkemi Growth Capital
New DelhiPre-Seed–Growth
15 people
DeepTech & Climate Fonds
MunichSeries A–Growth$5.5M – $55M
15 people
Sciety
StockholmSeed–Growth
21 people
Helium-3 Ventures
New YorkSeed–Series B
5 people
Green Pine Capital Partners
ShenzhenPre-Seed–Series B
2 people
Delos Capital
CambridgeSeed–Growth
13 people
Eaton Square
LondonSeries A–Growth
25 people
REMUS Capital
BostonPre-Seed–Series B$25K – $20M
9 people
Creathor Ventures
Bad HomburgSeed–Late Stage$540K – $10.8M
2 people
HBM Partners
ZugSeed–Late Stage$5M – $50M
6 people
V-Bio Ventures
GhentSeed–Series B$270K – $2.2M
13 people
SCI Ventures
LondonSeed–Series B
18 people
ACT Venture Capital
DublinSeed–Growth$1.1M – $16.2M
11 people
Bioqube Ventures
BrusselsPre-Seed–Series B$108K – $6.5M
17 people
Crossbeam Venture Partners
New YorkPre-Seed–Late Stage$1M – $1.5M
8 people
Amplitude Venture Capital
MontrealPre-Seed–Series B
16 people
DNA Capital
São PauloSeed–Late Stage$100K – $5M
15 people
CPT Capital
LondonPre-Seed–Late Stage
7 people
Related lists
Series B Investors & VC Firms (2951)Biotech Investors & VC Firms (2483)Biotech Seed Investors & VC Firms (2027)Series B Investors & VC Firms in North America (1738)Biotech Series A Investors & VC Firms (1627)Biotech Investors & VC Firms in North America (1601)Series B Investors & VC Firms in United States (1573)Biotech Investors & VC Firms in United States (1450)SaaS Series B Investors & VC Firms (1075)Series B Investors & VC Firms in Europe (1073)
Data sourced from public filings and firms' own websites — see our methodology.



































































































